In treatment-resistant neuroblastoma, BORIS-regulated alterations in enhancer–promoter interactions support advanced cancer phenotypes,92 suggesting a possibility that similar mechanisms could underlie the activation of other developmental programmes in cancer as well. Here, CTCFL is linked to cancer.